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Background: Lung cancer is one of the most lethal malignancies worldwide, but useful biomarkers of lung cancer
are still insufficient. The aim of this study is to identify some membrane-bound protein(s) associated with migration
and invasion in human non-small cell lung cancer (NSCLC) cells.
Methods: We classified four NSCLC cell lines into high and low migration/invasion groups by Transwell and
Matrigel assays. Using two-dimensional gel electrophoresis and matrix-assisted laser desorption ionization-time of
flight mass spectrometry (MALDI-TOF MS), we identified 10 membrane-associated proteins being significantly
overexpressed in the high migration/invasion group. The expression of the target protein in the four NSCLC cell
lines was then confirmed by reverse transcription polymerase chain reaction (RT-PCR), western blot and
immunostaining. RNA interference technique was applied to observe the influence of the target protein on
migration and invasion. Gelatin zymography was also performed to evaluate the activities of matrix
metalloproteinase (MMP)-2 and MMP-9. Expression condition of the target protein on surgical specimens was
further examined by immunohistochemical staining and the clinicopathologic data were analyzed.
Results: We identified a mitochondria-bound protein cytochrome c oxidase subunit Va (COX Va) because of its
abundant presence found exclusively in tumorous areas. We also demonstrated that migration and invasion of
NSCLC cells decreased substantially after knocking down COX Va by siRNA. Meanwhile, we found a positive
correlation between COX Va expression, Bcl-2 expression and activities of MMP-2 and MMP-9 in NSCLC cells.
Immunohistochemical staining of surgically resected lung adenocarcinomas in 250 consecutive patients revealed
that strong COX Va expression was found in 54.8% (137/250) of patients and correlated positively with the status of
lymph node metastasis (P= 0.032). Furthermore, strong COX Va expression was associated with the presence of
distant metastasis (P= 0.033).
Conclusions: Our current study showed that COX Va may play a role in migration and invasion of NSCLC cells and
can be used as a biomarker to predict aggressiveness of NSCLC.
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Lung cancer, predominantly non-small cell lung cancer
(NSCLC), is currently the leading cause of male cancer-
related death worldwide [1]. Despite application of
multimodal treatments, the overall survival of NSCLC
patients remains poor [2-4]. About 40-50% patients of
NSCLC present with stage IV disease [5], and given that
complete surgical resection may provide a chance of
cure in patients with early-stage tumors, the reported re-
currence rate in the patients with completely resected
stage I NSCLC was nearly 30% [6-8]. Moreover, among
these patients with tumor recurrence, more than 70% of
them have distant metastasis [6,8]. All these facts indi-
cate that metastasis is the most frequently encountered
problem in treating NSCLC. Metastasis is a complicated
process with tumor invasion being the first step, fol-
lowed by arrest in the blood stream, and finally meta-
static colonization [9]. However, molecular factors that
are related to invasion are still insufficient, and identifi-
cation of such factors with elucidation of their molecular
mechanism will provide insight into cancer biology and
potentially provide new therapeutic targets for NSCLC
patients.
The rapid development of proteomic technologies dur-
ing the past 10 more years has brought about a massive
increase in the discovery of novel cancer biomarkers.
The biomarkers may have broad applications, such as
for detecting the presence of a disease, monitoring the
status of the disease, or evaluating the treatment re-
sponse. The commonly used techniques to discover
these biomarkers, also referred to as quantitative proteo-
mics, are performed by protein separation using either
two-dimensional gel electrophoresis (2DE)- or liquid
chromatography (LC)-based methods coupled with pro-
tein identification using mass spectrometry (MS) [10].
Regarding lung cancer, Chen et al. used tissue samples
and quantitative proteomics to identify some proteins
involving in controlling gluconeogenesis and glycolysis
that were associated with the survival of patients with
early-stage lung adenocarcinoma [11]. Tian et al. applied
NSCLC cell lines plus 2DE, matrix-assisted laser desorp-
tion ionization-time of flight mass spectrometry
(MALDI-TOF MS) and tandem mass spectrometry to
recognize S100A11 as an important regulatory molecule
in promoting invasion and metastasis of NSCLC [12].
In the current study, we studied the non-secreted
membrane-bound proteins that are associated with mi-
gration/invasion in NSCLC cells. We separated four
NSCLC cell lines into high and low migration/invasion
group, and then comparatively analyzed the membrane
protein profiles between these two groups by conven-
tional 2DE followed by MALDI-TOF MS. A subunit of
cytochrome c oxidase (COX) called COX Va was chosen
to be the target of further study because of its presenceexclusively in tumorous areas but not in non-tumorous
areas in surgical specimens of NSCLC. The correlations
between COX Va expression and activities of matrix
metalloproteinase-2 (MMP-2), matrix metalloproteinase-
9 (MMP-9), and Bcl-2 expression were studied. The clin-
icopathologic significances of COX Va overexpression
were also evaluated in surgically resected lung adenocar-
cinomas in 250 consecutive patients by immunohisto-
chemical staining.
Methods
NSCLC cell lines, cell culture and surgically dissected
tumor samples
The cell lines CL1-1 and CL1-5 were sublines with dif-
ferent invasiveness derived from the same parental line
[13]. To increase the discrimination power of the study,
we added two more NSCLC cell lines that exhibited dif-
ferent abilities of migration/invasion. Two human
adenocarcinoma cell lines were purchased from Ameri-
can Type Culture Collection (ATCC) (Manassas, VA):
H2126 (ATCC No. CCL-256) and H2009 (ATCC No.
CRL-5911). The CL1-1 and CL1-5 were kind gifts from
Professor Pan-Chyr Yang at National Taiwan University.
Cells were cultured in the RPMI 1640 medium (GIBCO,
Gaithersburg, MD) containing 10% fetal bovine serum
(FBS) (Jacques Boy, Reims, France), 100 U/mL penicillin
(GIBCO) and 100 U/mL streptomycin (GIBCO) at 37°C
in a 5% CO2 atmosphere at 99% humidity. A total of 250
surgically resected tumor samples, confirmed to be
adenocarcinoma by histopathologic examinations, were
obtained from consecutive patients with NSCLC be-
tween 2000 and 2005. Written informed consents were
obtained from the patients with the study protocol
approved by the ethical committee of the hospital.
Migration assay
Cell migration assays were performed using Boyden cham-
ber assay. The procedures were performed according to the
manufacturer’s recommended protocol and had been previ-
ously described [13]. Cells were harvested and suspended
in RPMI 1640 medium containing 10% FBS at a concentra-
tion of 5×104 cells/mL. A Transwell apparatus with 8 μm
pore size membrane (Millipore, Billerica, MA) was used to
analyze the migration activity. The suspended cells in
100 μL of serum-free RPMI 1640 medium were
seeded onto the upper chamber of the apparatus and
250 μL of RPMI containing 10% FBS were added to
the insert well followed by an incubation at 37°C for
6 hours. The inner side of the chamber was then
wiped with a wet swab to remove the cells, while the
outer side of the chamber was gently rinsed with PBS
and subjected to Giemsa staining (Sigma-Aldrich, St.
Louis, MO) for 10 minutes. The membrane was then
rinsed with phosphate-buffered saline (PBS). After
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counting the cell number. Each cell line was evalu-
ated in triplicate.
Invasion assay
Invasion assay was performed by a modification of the
method previously described [14]. One hundred μL
Matrigel (Becton Dickinson, Franklin Lakes, NJ) diluted
to 1 mg/mL in serum-free RPMI was added to each
upper chamber of the Transwell apparatus. After solidifi-
cation of Matrigel at 37°C, approximately 5 × 104 cells in
serum-free RPMI were seeded onto the Matrigel over
the upper chamber, followed by an addition of 250 μL of
RPMI containing 10% FBS at the bottom insert-well.
After incubation of the cells at 37°C for 18 hours, the
inner side of the chamber was wiped with a wet swab to
remove the cells, while the outer side of the chamber
was gently rinsed with PBS and stained with the Giemsa
stain solution for 10 minutes. Finally, the membrane was
rinsed and allowed to air-dry. The membrane was
photographed followed by counting the cell number and
each cell line was evaluated in triplicate.
Preparation of protein extract from membranes
A total of 2× 106 each NSCLC cells were suspended and
washed by PBS for three times, followed by centrifugation
at 1,500 g for 5 minutes. Cell membranes were isolated and
extracted by a Compartment Protein Extraction Kit (Bio-
Chain Institute, Hayward, CA) following the procedures
described by the manufacturer.
2D Gel electrophoresis
Immobilized 13-cm linear pH gradient strips, pH 3-11,
were rehydrated overnight in a rehydration buffer con-
taining 7 M urea, 2 M thiourea, 4% CHAPS, 0.5% gradi-
ent buffer and 50 mM dithiothreitol (DTT) according to
the manufacturer's instructions (Amersham Biosciences,
Buckingham, UK). Isoelectrofocusing was performed at
20°C using an IPGphor apparatus (Amersham) with 50
mA for a total of 40 kV/h. Strips were equilibrated in 50
mM Tris–HCl, 6 M urea, 30% (v/v) glycerol, 1% (w/v)
sodium dodecyl sulfate (SDS) and 65 mM DTT, pH 8.8
for 20 minutes in the same buffer containing 240 mM
iodoacetamide. Equilibrated strips were transferred onto
15% uniform polyacrylamide gels poured between the
two glass plates (18 × 20 cm). Strips were overlaid with
0.5% (w/v) low melting point agarose prepared in a run-
ning buffer containing bromphenol blue. Gels were run
at 10°C using the Ettan Dalt 6 apparatus (Amersham) at
2.5 W/gel for 30 minutes with 30 mA in total until the
dye front run off the bottom of the gels. All the images
were collected on a Typhoon 9400 Variable Mode
Imager (Amersham). Statistics and determination ofprotein expression levels were carried out by a Decyder
software (Amersham).MALDI-TOF MS
Protein spots were excised manually from Coomassie
blue-stained gels and washed twice in 25 nM NH4HCO3
for 10 minutes until the gel pieces become transparent.
Gel pieces were dehydrated with 100% acetonitrile for 5
minutes and allowed to dry, followed by incubation with
15 μL of a 12.5 ng/μL trypsin solution at 37°C overnight.
Trypsinized samples were then concentrated using a
C18 Zip-Tips Kit (Millipore) and eluted with 50% aceto-
nitrile/0.1% trifluroacetic acid according to the manufac-
turer’s instructions. Identification of peptides was
performed using a Microflex MALDI-TOF LRF20 mass
spectrometer (Bruker Daltonics, Billerica, MA). The Zip-
Tips-purified peptide digests were spotted with a cyano-
4-hydroxycinnamic acid matrix and run in reflection
positive-ion mode at an accelerating voltage of 25 kV.
Subsequently, protein identification was done using
MASCOT search engine from SWISS-PROT database
(http://www.matrixscience.com).Reverse transcription polymerase chain reaction (RT-PCR)
Level of mRNA expressions corresponding to COX Va
and other genes in NSCLC cells were determined by RT-
PCR. Total RNA was extracted from cells using a SNAP
RNA column (Invitrogen Corporation, San Diego, CA).
Following spectrophotometric determination of RNA
yield, cDNA is synthesized with oligo(dT) primer using
avian myeloblastosis virus (AMV) reverse transcriptase.
An aliquot of cDNA was subjected to 35 cycles of PCR
using a standard procedure denaturing at 94°C for 30 sec-
onds, hybridizing at 57°C for 30 seconds and elongating at
72°C for 1 minute. Amplified products were resolved in
a 1 % agarose gel and visualized by ethidium bromide
staining. DNA sequences of the amplified fragment
were determined by an automatic sequenator (ABI, Fos-
ter City, CA) with the nucleotide sequences matched
with the database from GenBank (http://www.ncbi.nlm.
nih.gov/blast). The primer sequences used were as fol-
lows: COX Va (forward) 5’- TCGCCGTCATGCTGGG -
3’ and (reverse) 5’- CAATAAATCCTTGGGGAAGCC -
3’, MMP-2 (forward) 5’- AGAAGGCTGTGTTCTTTG
CAG -3’ and (reverse) 5’- AGGCTGGTCAGTGGCTTG
-3’, MMP-9 (forward) 5’- ATCCGGCACCTCTATGGTC
-3’ and (reverse) 5’- GCTCTGAGGGGTGGACAGT -3’,
Bcl-2 (forward) 5’- ATGTGTGTGGAGAGCGTCAACC
-3’ and (reverse) 5’- TGAGCAGAGTCTTCAGAGACA
GCC -3’. The primer sequences for the house-keeping
gene β-actin were (forward) 5’- CCAGATCATGTTT
GAGACCT -3’ and (reverse) 5’- CAACTAAGTCA
TAGTCCGCC -3’.
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SDS-PAGE containing 15% polyacrylamide (unless speci-
fied otherwise) was used to analyze the COX Va content
using a modified procedure described previously [15].
Electrophoresis was conducted in a vertical slab gel unit
(Mini PIII, Bio-Rad, Hercules, CA) equipped with a PAC
300 power supply (Bio-Rad). All samples (20 μg) for
SDS-PAGE were equilibrated in 10 mM Tris-HCl and
5% SDS (pH 7.6) before loading onto the gel. Following
electrophoresis, the gel was soaked briefly and instantly
in a transfer buffer containing 25 mM Tris, 192 mM gly-
cine, 20% methanol, and 0.0375% SDS (pH 8.3) for 30
seconds. The gel was then immediately electrotrans-
ferred to a nitrocellulose membrane (Hybond-ECL extra;
Amersham) at 90 mA for 60 minutes in a semi-dry
Transfercell (Bio-Rad). The membrane was immersed in
1% skin milk for 1 h with gentle shaking. Following three
washes with PBS for 5 minutes each, the membrane was
subjected to reaction with a mouse monoclonal antibody
against COX Va (MitoScience, Eugene, OR) at a 1:1,000
dilution and developed with chemiluminescence accord-
ing to the method described previously [15].
COX Va gene knockdown
The small interfering RNA (siRNA) targeting human COX
Va was designed using a BLOCK-iT RNAi Designer algo-
rithm (http://rnaidesigner.invitrogen.com/rnaiexpress/). To
avoid unintentional silencing of non-targeted host cell
genes, sequence homology was checked using a basic local
alignment search tool (BLAST) search (http://blast.ncbi.
nlm.nih.gov/Blast.cgi). A scrambled-sequence oligonucleo-
tide (CAAAGCAGGACCTCATAAGGAAATCTACC) was
used as a negative siRNA control. Pairs of complementary
oligonucleotides sequences were synthesized, annealed and
cloned into the pRS shRNA vector (OriGene, Rockville,
MD). NSCLC cells were transfected with one of the four
shRNAs using TurboFect™ (Fermentas, Glen Burnie, MD)
as described below. After 48 hours, COX Va expression
was assessed using RT-PCR. The results showed that two
COX Va siRNA (ACTTGTTACCTATGATATGGTTCCA
GAGC and CCTATGTCATCCAGGAACTTAGACC
AACT) possessed the highest activity to suppress the ex-
pression of COX Va, and were used for subsequent
experiments.
Transfection of siRNA
TurboFect™ was used to deliver plasmid DNA containing
siRNA against human COX Va (shCOX Va) into NSCLC
cells in a 24-well culture plate. In each well, approxi-
mately 5x104 cells in 1 mL was seeded and grown for 24
hours prior to transfection. While gently shaking, 1 μg
of plasmid in 100 μL of RPMI medium was slowly added
into 2 μL of TurboFect™ and incubated at room
temperature for 15-20 minutes. The reaction mixturewas then transfected into cells, which were grown in the
culture medium containing 2 μg/mL puromycin for an-
other 3 days, while plasmid without shRNA was used as
a negative control.
Gelatin zymography
To determine the enzyme activities of MMP-2 and
MMP-9, media derived from the NSCLC cells cultured
for 48 hours were used for the gelatin zymography
[16,17]. An aliquot of 10 μL culture medium was loaded
onto a SDS-PAGE gel under non-reducing conditions
using an 8% polyacrylamide gel containing 0.1 mg/mL
gelatin. After electrophoresis, the gels were washed 3
times in 2.5% (w/v) and treated with Triton X-100 for 30
minutes at room temperature to remove the SDS and
then incubated in a reaction buffer containing 50 mM
Tris (pH 7.4), 5 mM CaCl2 and 150 mM NaCl for 24
hours at 37°C, followed by staining with 2.5% (w/v) Coo-
massie blue in 30% (v/v) methanol and 10% (v/v) acetic
acid. The MMP-2 and MMP-9 activities were detected
as clear bands on a blue background with stained un-
digested gelatin.
Immunocytochemical staining of cultured cells
Glass cover slips were sterilized by dipping them in 90%
ethanol. After drying over a flame, each slip was placed
into each well of 6-well culture plates. NSCLC cells
(5 × 106) in 2 mL of RPMI medium containing 10% FBS
were seeded over the slip and grown at 37°C until 50-70
% confluence reached. Following removal of the culture
medium, cells in each well were rinsed twice with PBS
and fixed with 3% paraformaldehyde (Sigma) in PBS and
then incubated at room temperature for 20 minutes.
After rinses with PBS for three times, cells were treated
with a Triton X-100 buffer containing 50 mM Tris, 1
mM EDTA and 0.5% Triton X-100, pH 8.0 at room
temperature for 15 minutes. Following washes with
PBS, the slips were incubated with 10% normal horse
serum to block nonspecific staining and then incubated
with a mouse monoclonal antibody against COX Va
(MitoScience, Eugene, OR) at a 1:100 dilution in a
humid chamber at 4°C overnight. After washes, cells
were incubated with a biotinylated horse anti-mouse
IgG for 30 minutes and incubated with streptavidin-
conjugated peroxidase for 30 minutes. Cells containing
COX Va were visualized by incubation with 3,3-diami-
nobenzidine solution (0.3% hydrogen peroxide and
0.05% 3,3-diaminobenzidine) and counterstained with
hematoxylin. Negative controls were prepared by substi-
tuting a normal mouse IgG as the primary antibody.
Preparation of tissue core array
All of the pathologic sections were reviewed by one
pathologist (T.Y.C.). Cores of tissue in demand were
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inge needle as described previously [18]. The cores were
placed in a warm cast containing partially melted paraf-
fin and arranged into a 6 x 8 array with one core at the
upper-left corner removed as an orientation marker.
Each array contained 47 cores with each patient sample
from two to five cores, depending on the availability of
tissue blocks. The positions of each core were recorded
on reference sheets to facilitate data acquisition.
Immunohistochemical staining of tumor tissues and
evaluation of COX Va immunostaining
Immunostaining was performed by biotin-streptavidin-
peroxidase procedures using a Vectastain ABC Kit (Vec-
tor Laboratories, Burlingame, CA). Fresh tumor tissues
from patients with NSCLC and tissue core arrays were
fixed in formalin and embedded in paraffin, to which
sliced serial sections in 4 μm were mounted on glass
slides, deparaffinized with xylene and dehydrated with
alcohol according to the manufacturer’s instructions.
Following retrieval of the antigen by heating the slice inFigure 1 Differences in migration ability among four NSCLC cell lines
Transwell assay. Each bar represents the mean± SD (standard deviation) of
difference (P< 0.001) between either H2009 or CL1-5 and CL1-1 or H2009.a microwave for 2 minutes at 900W, the slides were
incubated with 0.3% H2O2 solution in methanol for 30
minutes to block endogenous peroxidase. After rinses
with PBS for three times, the tissues were treated with
protease K (20 μg/mL a buffer containing 50 mM Tris,
1mM EDTA, 0.5% Triton X-100, pH 8.0) for 15 minutes
at room temperature to expose the immunoreactive
parts of COX Va on the mitochondrial membrane.
Thereafter, the rest of the immunostaining procedures
were conducted according to that described above.
Each stained core was evaluated according to the gross
percentage of cells demonstrating nuclear and cytoplasmic
immunoreactivity on the tumor part, and the assessment
was accomplished independently by two examiners (W.L.
C and K.T.K.). The scoring criteria for COX Va were as
follows: 0, no appreciable staining in cells; 1+, appreciable
nuclear staining with cytoplasmic staining in <25% of
cells; 2+, appreciable nuclear staining with cytoplasmic
staining between 25% and 50% of cells; 3+: appreciable
nuclear staining with cytoplasmic staining in >50% of
cells. Only 3+ staining was defined as COX Va(H2126, CL1-1, CL1-5 and H2009). Migration ability was assessed by
the results from triplicates. The asterisk indicates a significant
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sion was classified according to the 6th edition American
Joint Committee on Cancer (AJCC) Staging System.
Statistical analysis
The data were analyzed and are presented as mean±SD
(standard deviation). The difference between the com-
pared groups was calculated by Mann-Whitney U test.
Pathologic T, N, M status and tumor stage derived from
new lung cancer staging system in the database were
reviewed. The relationship between pathologic factors and
COX Va expression status was analyzed by χ2 test (or
two-tailed Fisher’s exact test when the expected number




We evaluated four NSCLC cell lines (CL1-1, CL1-5,
H2126 and H2009) for their abilities in cell migration
and invasion. As shown in Figures 1 and 2, those cell
lines had stronger migration also had stronger invasion.Figure 2 Differences in invasion ability among four NSCLC cell lines (
Matrigel assay. Each bar represents the mean± SD of the results from triplic
either H2009 or CL1-5 and CL1-1 or H2009.Thus we divided them into low (H2126 and CL1-1) and
high (CL1-5 and H2009) migration/invasion group.
2D Gel electrophoresis analysis
Next, we analyzed the membrane protein profiles be-
tween the high and low migration/invasion groups by
2D PAGE. A representative example of the comparison
is depicted in Figure 3. The proteins overexpressed in
high migration/invasion group were selected as targets
since they might serve as potential biomarkers in a usual
pathology laboratory. Following MALDI-TOF MS ana-
lyses, we identified 10 proteins, with their details listed
in Table 1. Among them, one mitochondrial membrane-
bound protein called cytochrome c oxidase subunit Va
(COX Va), was of most interest because it was markedly
overexpressed in tumorours tissues.
Characterization of molecular and protein expression of
COX Va in NSCLC cell lines by RT-PCR, western blot and
immunocytochemical staining
To evaluate whether this newly identified protein COX Va
was overexpressed in situ in the cells with high migration/H2126, CL1-1, CL1-5 and H2009). Invasion ability was assessed by
ates. The asterisk indicates a significant difference (P< 0.001) between
Figure 3 A typical example of membrane-associated proteins analyzed by 2D-gel between low (CL1-1) and high (CL1-5) migration/
invasion lung cancer cell lines. A sample containing 200 μg of membrane proteins was initially run by isoelectrofocusing (pH 3 to 10 from left
to right), which was followed by a conventional SDS-PAGE. Gels were then stained with a silver staining solution.
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using RT-PCR. Figure 4A shows that the cell lines in high
migration/invasion group had greater COX Va mRNA
levels as compared with those in low migration/invasion
group. The higher expression in protein level was also
documented by western blot, as shown in Figure 4B. To
further confirm these observations, we determined the
level of COX Va using an immunostaining in these four
cell lines. Pre-immune serum or unrelated monoclonal
antibody was used as a negative control. After treatment
of the cells with Triton X-100, Figure 4C shows that there
was a striking difference in immunostaining activity be-
tween the high and low migration/invasion cells. These
results confirmed that the cell lines in high migration/in-
vasion group had higher intensity of COX Va expression.
Decreased migration/invasion of NSCLC cells by knocking
down COX Va
To further testify whether COX Va plays a role in tumor
cell migration/invasion, we constructed shRNA toTable 1 Up-regulated proteins in highly migration/invasion N
Protein name Molecular weight (kDa)
COX Va 16.7 mitocho
Caveolin-1 25
Galectin-1 14
Galectin-3 35 cytosol and M
Glucose-regulated protein 78 78 end
Heat shock 70 kDa protein 8 70 end
Tyrosine-protein kinase 7; AXL 107
Trophinin 70
UDP-glucuronosyltransferase 56 end
Vimentin 57knockdown COX Va at its mRNA level in the high mi-
gration/invasion group, with the H2009 cells as the rep-
resentative. The result of RT-PCR (Figure 5A) shows
that the expression of COX Va mRNA was substantially
attenuated in COX Va-knockdown cells comparing with
original H2009 (control) or scramble. Furthermore, cells
with COX Va-knockdown had 42% decrease in migra-
tion and 52% decrease in invasion, respectively, as com-
pared with original H2009 (control) or scramble
(P< 0.01) (Figure 5B and 5C). These findings suggest
that expression of COX Va was associated with migra-
tion/invasion of NSCLC cells.
MMP assay
To look into the factors that were possibly linked to
COX Va expression, we examined the expression of
MMP-2 and MMP-9 in these four NSCLC cells. In
addition to RT-PCR, we used gelatin zymography to
assess the enzyme expression of MMP-2 and MMP-9.
Figure 6A and 6B show that cell lines with highSCLC cell lines
Location Function
ndria inner membrane electron carrier activity
membrane protein Tyrosine Phosphatase and
G-protein–mediated signal transduction
membrane regulate apoptosis, cell proliferation and
differentiation
itochondria inner membrane cell differentiation
oplasmic reticulum involved in the folding and assembly
of proteins
oplasmic reticulum protein refolding and antiapoptosis,
membrane signal transducer
membrane adhesion molecule
oplasmic reticulum bilirubin conjugation
cytoskeleton cellular component movement
Figure 4 Comparison of the expression of mRNA and protein of COX Va in NSCLC cell lines using RT-PCR, western blot and
immunocytochemical staining. (A) RT-PCR. A quantification plot is also illustrated. (n= 3). (B) Western blot. Each sample containing 10μg membrane
proteins was loaded on a 15% SDS-PAGE. (C) Immunocytochemical staining was performed by using a monoclonal antibody against COX Va.
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pression of MMP-2 and MMP-9 comparing to those
with low migration/invasion (H2126 and CL1-1), in
mRNA and enzyme activity level, respectively. These
findings may partly account for why CL1-5 and H2009
had higher migration/invasion than did H2126 and
CL1-1. Furthermore, the enzyme activity of MMP-2 and
MMP-9 was also shown to be reduced in COX Va
knockdowned H2009 cells (Figure 6C).
Bcl-2 evaluation
Bcl-2 and its family proteins are integral membrane pro-
teins located mainly on the outer membrane of mito-
chondria and have been reported to interact with
cytochrome c [19,20]. Therefore, the mRNA expression
of Bcl-2 in four cell lines was also evaluated. As shown
in Figure 7A, the cell lines in high migration/invasion
group (CL1-5 and H2009) had higher expression of Bcl-
2 mRNA. After knocking down COX Va expression, the
H2009 cells with COX Va-knockdown also had lower
expression of Bcl-2 mRNA (Figure 7B).
Expression of COX Va in surgically resected tissues of
patients with NSCLC
Paired tumorous and non-tumorous (stromal area) fresh
frozen specimens from 10 subjects with NSCLC wererandomly selected to evaluate the mRNA expression of
COX Va by RT-PCR. It revealed that the expression con-
dition of COX Va mRNA was variable, with greater level
in tumorous area in most cases (Figure 8A). With respect
to immunostaining in the fresh resected tissues, it was of
interest to note that COX Va can only be stained by treat-
ing the tumorous tissue with Triton X-100 plus protease
K. A typical example showing tumorous area being highly
positive is depicted in Figure 8B. To our surprise, we
found that non-tumorous areas were essentially negative
for COX Va, which is similar to negative controls stained
with normal mouse serum (data not shown). However, it
should be reminded that areas without reactivity in immu-
nostaining do not necessarily indicate a lack of biosyn-
thesis of COX Va. For example, expression of COX Va
mRNA in non-tumorous tissue could still be observed in
subject No.3, 4 and 8 (Figure 8A).
Using tissue core array, we also studied the immunor-
eactivities of COX Va in formalin-fixed, paraffin-
embedded specimens and analyzed their pathologic sig-
nificance in 250 consecutive patients with adenocarcin-
oma. Strong COX Va expression was found in 54.8% (137/
250) of patients and correlated positively with the N status
(P=0.032), but without significant correlation with T sta-
tus (P=0.667), M status (P=0.802) or stage (P= 0.232)
(Table 2). During follow-up, strong COX Va expression
Figure 5 The effect of COX Va gene knockdown on the migration/invasion of NSCLC cells. (A) RT-PCR for COX Va in original H2009 cells
(control), scramble and H2009 cells transfected with the shRNA against human COX Va. A quantification plot is also illustrated. (n = 3).
(B) Migration activity of H2009 cells following transfection. Each bar represents the mean± SD of the results from triplicates. (C) Invasion activity
of H2009 cells following transfection. Each bar represents the mean± SD of the results from triplicates. The asterisk indicates a significant
difference (P< 0.01) between either original H2009 (control) or scramble and COX Va-knockdown cells.
Figure 6 Studies of MMP-2 and MMP-9 in NSCLC cells. (A) RT-PCR for MMP-2 and MMP-9 in four NSCLC cell lines. A quantification plot is also
illustrated. (n = 3). (B) Gelatin zymography of enzyme activity determined from concentrated culture media of four NSCLC cell lines after 48 hours
of incubation. (C) MMP-2 and MMP-9 activities in original H2009 cells (control), scramble and COX Va-knockdown H2009 cells.
Chen et al. BMC Cancer 2012, 12:273 Page 9 of 13
http://www.biomedcentral.com/1471-2407/12/273
Figure 7 Bcl-2 expression in NSCLC cells. (A) RT-PCR for Bcl-2 in four NSCLC cell lines. A quantification plot is also illustrated. (n = 3). (B) RT-PCR
for Bcl-2 in original H2009 cells (control), scramble and COX Va-knockdown H2009 cells. A quantification plot is also illustrated. (n = 3).
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(P=0.033) but not local recurrence (P=0.465). However,
COX Va expression was not associated with either overallFigure 8 Molecular expression and immunostaining of COX Va in pai
NSCLC. (A) RT-PCR. (B) Immunohistochemical staining. A typical example d
in non-tumorous tissues (left).survival (P=0.329) or disease-free survival (P=0.189).
The median survival was 65.1 months for strong COX Va
patients, and 69.8 months for weak COX Va patients.rs of surgically resected lung tissues from 10 patients with
epicts a positive immunostaining in tumorous tissues (right), but not
Table 2 Relationship between COX Va expression and
clinicopathologic parameters











N (-) 83 83
N (+)a 54 30
M status 0.802
M (-) 130 108






Local yes 9 5 0.465
recurrence no 128 108
Distant yes 25 10 0.033*
metastasis no 112 103
aN(+) includes N1and N2 but without N3.
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Metastasis remains the major problem in managing
NSCLC, and invasion is the first step of metastasis. Thus
understanding more about invasion will provide us greater
opportunities to treat NSCLC. Previous reports [21,22]
have concluded some markers regarding metastasis and
invasion in lung cancer, such as MMPs, vascular endothe-
lial growth factor (VEGF) and cyclooxygenase-2 (COX-2).
Among these markers, some therapeutic agents derived
from them had been proved to be useful in clinical practice
[23-25].
In this study, using NSCLC cell lines with different
abilities of migration/invasion, we distinguished a
membrane-bound protein that was associated with mi-
gration/invasion of NSCLC by proteomic approach. To-
tally 10 membrane-associated proteins were identified
after 2D gel electrophoresis and subsequent MALDI-
TOF MS studies, and COX Va was of particular interest
because of its exclusive presence in the surgical speci-
mens from NSCLC patients. Further experiments sup-
ported the assumption that COX Va was associated with
migration/invasion of NSCLC.
First, knockdown of COX Va gene expression sup-
pressed migration/invasion of NSCLC cells effectively
(Figure 5). Second, the cells expressed higher level ofCOX Va also had higher expressions and activities of
MMP-2 and MMP-9 (Figure 6A and 6B), which had
been reported to be related to migration and invasion in
different types of tumor cells [16,17,26-28]. Meanwhile,
such a correlation was confirmed again in COX Va
knockdown study (Figure 6C). Third, in 250 surgically
resected adenocarcinomas, overexpression of COX Va
correlated positively with the N status (lymph node me-
tastasis) and distant metastasis. These data highlighted
the clinicopathologic role of COX Va.
Structurally, COX is a mitochondrial transmembrane
enzyme consisting of 13 subunits in mammals, among
which only the three largest subunits (I-III) are encoded
by mitochondrial DNA. COX is a rate-limiting enzyme
present as a dimeric unit participating at the terminal
step in respiratory chain to reduce molecular oxygen
into water and pump protons across the inner mito-
chondrial membrane [29-32]. A recent study showed
that high levels of COX activity and mitochondrial res-
piration in tumor cells lead to an overexpression of Bcl-
2 [33]. Furthermore, it has been reported that Bcl-2 dir-
ectly binds to COX to promote survival of cancer cells
by maintaining a slight pro-oxidant state through ele-
vated mitochondrial respiration during basal conditions
[34]. In the same study, a protein-protein interaction be-
tween COX Va and Bcl-2 was also documented by
coimmunoprecipitation.
Although the causal relationship between COX Va and
MMP-2/MMP-9 could not be demonstrated in the
current study, some speculation may be provided. From
our current data, the cell lines in high migration/inva-
sion group (CL1-5 and H2009) also had higher expres-
sion of Bcl-2 and knocking down COX Va was
associated with decreased expression of Bcl-2. It implied
that the activity of COX Va was parallel to the expres-
sion of Bcl-2. Previously, it has been reported that Bcl-2
promotes invasion and lung metastasis by inducing
MMP-2 in NSCLC cells [35] and coexpression of Bcl-2
and N-Myc induces MMP-2 secretion and activity in
human neuroblastoma cells [36]. In an animal study,
down-regulation of Bcl-2 was observed to be associated
with down-regulation of both MMP-2 and MMP-9 ex-
pression [37]. Thus we consider that overexpression of
COX Va may result in increased expression of MMP-2
and MMP-9 via collaboration with Bcl-2. Nevertheless,
further investigations are needed to elucidate the mech-
anistic insight.
Conclusions
To sum up, we identified a membrane-bound protein
COX Va from NSCLC cells with different abilities of mi-
gration/invasion and confirmed its relationship to migra-
tion/invasion by several in vitro experiments. The
clinicopathologic role of COX Va was also demonstrated
Chen et al. BMC Cancer 2012, 12:273 Page 12 of 13
http://www.biomedcentral.com/1471-2407/12/273by its positive correlation with lymph node metastasis in
surgically resected adenocarcinomas plus prediction of
distant metastasis during follow-up. Meanwhile, expres-
sion of COX Va was found parallel to expression of Bcl-
2, MMP-2 and MMP-9. All these data suggested that
COX Va plays a role in migration/invasion of NSCLC
cells and is worth of further study to serve as a thera-
peutic target in NSCLC.
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